NDFOS Co. Ltd (238090) - Total Liabilities
Based on the latest financial reports, NDFOS Co. Ltd (238090) has total liabilities worth ₩14.82 Billion KRW (≈ $10.04 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of NDFOS Co. Ltd's assets are long-term investments to see how much of total assets are deployed in long-term investments.
NDFOS Co. Ltd - Total Liabilities Trend (2014–2024)
This chart illustrates how NDFOS Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see NDFOS Co. Ltd assets under control.
NDFOS Co. Ltd Competitors by Total Liabilities
The table below lists competitors of NDFOS Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Quest Resource Holding Corp
NASDAQ:QRHC
|
USA | $107.49 Million |
|
ilShinbiobase Co. Ltd
KQ:068330
|
Korea | ₩6.72 Billion |
|
Kayee International Group Co Ltd
TW:2939
|
Taiwan | NT$250.11 Million |
|
Asia Precision Public Company Limited
BK:APCS
|
Thailand | ฿1.54 Billion |
|
Borealis Foods Inc.
NASDAQ:BRLS
|
USA | $69.25 Million |
|
Bintai Kinden Corporation Bhd
KLSE:6998
|
Malaysia | RM154.83 Million |
|
Primary Health Properties
LSE:PHP
|
UK | GBX3.54 Billion |
|
Centric Holdings S.A
AT:CENTR
|
Greece | €11.16 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down NDFOS Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See NDFOS Co. Ltd (238090) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NDFOS Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NDFOS Co. Ltd (2014–2024)
The table below shows the annual total liabilities of NDFOS Co. Ltd from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩15.70 Billion ≈ $10.64 Million |
-5.75% |
| 2023-12-31 | ₩16.66 Billion ≈ $11.29 Million |
-51.77% |
| 2022-12-31 | ₩34.55 Billion ≈ $23.41 Million |
-50.44% |
| 2021-12-31 | ₩69.71 Billion ≈ $47.24 Million |
+67.85% |
| 2020-12-31 | ₩41.53 Billion ≈ $28.15 Million |
-47.23% |
| 2019-12-31 | ₩78.70 Billion ≈ $53.34 Million |
+71.88% |
| 2018-12-31 | ₩45.79 Billion ≈ $31.03 Million |
+275.02% |
| 2017-12-31 | ₩12.21 Billion ≈ $8.27 Million |
+47.33% |
| 2016-12-31 | ₩8.29 Billion ≈ $5.62 Million |
-20.84% |
| 2015-12-31 | ₩10.47 Billion ≈ $7.09 Million |
-23.81% |
| 2014-12-31 | ₩13.74 Billion ≈ $9.31 Million |
-- |
About NDFOS Co. Ltd
NDFOS Co., Ltd. operates as a tape and film company in South Korea. The company offers adhesive tapes, such as waterproof tapes, light-shielding tapes, heat reaction tapes, battery fixing tapes, thin film tapes, convergence type functional tapes, and heat radiation tapes; functional films, including automobiles, industries, and everyday life. It also develops ARS and STR, anticancer drugs for can… Read more